CA-PROM: Validation of a general patient-reported outcomes measure for Chinese patients with cancer

被引:4
作者
Hu, Xiaojuan [1 ]
Zhao, Zhiqiang [2 ]
Zhang, Shao-Kai [3 ]
Luo, Yanhong [1 ]
Yu, Hongmei [1 ]
Zhang, Yanbo [1 ]
机构
[1] Shanxi Med Univ, Sch Publ Hlth, Dept Hlth Stat, 56 South XinJian Rd, Taiyuan 030001, Shanxi, Peoples R China
[2] Shanxi Canc Hosp, Dept Hematol, 3 Workers New Village, Taiyuan 030013, Shanxi, Peoples R China
[3] Zhengzhou Univ, Dept Canc Epidemiol, Off Henan Canc Ctr, Affiliated Canc Hosp,Henan Canc Hosp, Zhengzhou 450008, Peoples R China
关键词
Cancer; Patient-reported outcome; Generalized partial credit model; Ordinal bayesian instrument development; Minimum clinically important differences; Risk thresholds of PRO; QUALITY-OF-LIFE; STATISTICS; PERFORMANCE; WINBUGS;
D O I
10.1016/j.canep.2020.101774
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Based the important role of patient-reported outcome in measuring patients' QoL, a general PRO instrument was designed for Chinese patients with cancer. Methods: The instrument was administered in eight hospitals. Based on PRO guidelines, a conceptual framework and item pool were generated after literature review and patients' interviews. Via two-item selection process, the original version of a cancer PRO measure (CA-PROM) was generated. Patients' responsiveness was evaluated in four disease systems by item response theory. The reliability, validity, and feasibility of CA-PROM were assessed. The minimum clinically important differences (MCIDs) and risk thresholds of PRO were calculated. Results: A total of 2213 valid questionnaires were collected. After expert opinions and cognitive tests, 11 items were deleted. In the pre-survey and formal survey, 19 items were deleted based on six methods of classical test theory. In the respiratory, digestive, hematological, and endocrine systems, four items with poor responsiveness were deleted by item response theory. The final CA-PROM included four domains, 13 subdomains, and 49 items. Reliability coefficients of 13 subdomain was > 0.7. The framework of CA-PROM ma required criteria by CFA and OBID. The average response time was 14.2 min, indicating feasibility of CA-PROM. The MCIDs were 5.63, 3.42, 4.16 in the physiological, psychological, social domain, respectively. The risk thresholds of PRO for six subdomains were 71.74, 71.28, 66.29, 65.16, 59.56, 66.60, in that order. Conclusion: The developed CA-PROM exhibited good reliability, validity, and feasibility, and can be used as an effective evaluation tool in cancer patients.
引用
收藏
页数:10
相关论文
共 42 条
[1]   THE EORTC MODULAR APPROACH TO QUALITY-OF-LIFE ASSESSMENT IN ONCOLOGY [J].
AARONSON, NK ;
CULL, A ;
KAASA, S ;
SPRANGERS, MAG .
INTERNATIONAL JOURNAL OF MENTAL HEALTH, 1994, 23 (02) :75-96
[2]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[3]   Confirmatory Factor Analysis Alternative: Free, Accessible CBID Software [J].
Bott, Marjorie ;
Karanevich, Alex G. ;
Garrard, Lili ;
Price, Larry R. ;
Mudaranthakam, Dinesh Pal ;
Gajewski, Byron .
WESTERN JOURNAL OF NURSING RESEARCH, 2018, 40 (02) :257-269
[4]   Feedback on the FDA's February 2006 draft guidance on Patient Reported Outcome (PRO) measures from a developer of PRO measures [J].
Bradley, Clare .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2006, 4 (1)
[5]   THE ROLE OF FACTOR-ANALYSIS IN THE DEVELOPMENT AND EVALUATION OF PERSONALITY-SCALES [J].
BRIGGS, SR ;
CHEEK, JM .
JOURNAL OF PERSONALITY, 1986, 54 (01) :106-148
[6]   Overview of Classical Test Theory and Item Response Theory for the Quantitative Assessment of Items in Developing Patient-Reported Outcomes Measures Comment [J].
Cappelleri, Joseph C. ;
Lundy, J. Jason ;
Hays, Ron D. .
CLINICAL THERAPEUTICS, 2014, 36 (05) :648-662
[7]   THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY SCALE - DEVELOPMENT AND VALIDATION OF THE GENERAL MEASURE [J].
CELLA, DF ;
TULSKY, DS ;
GRAY, G ;
SARAFIAN, B ;
LINN, E ;
BONOMI, A ;
SILBERMAN, M ;
YELLEN, SB ;
WINICOUR, P ;
BRANNON, J ;
ECKBERG, K ;
LLOYD, S ;
PURL, S ;
BLENDOWSKI, C ;
GOODMAN, M ;
BARNICLE, M ;
STEWART, I ;
MCHALE, M ;
BONOMI, P ;
KAPLAN, E ;
TAYLOR, S ;
THOMAS, CR ;
HARRIS, J .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :570-579
[8]   Cancer Statistics in China, 2015 [J].
Chen, Wanqing ;
Zheng, Rongshou ;
Baade, Peter D. ;
Zhang, Siwei ;
Zeng, Hongmei ;
Bray, Freddie ;
Jemal, Ahmedin ;
Yu, Xue Qin ;
He, Jie .
CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) :115-132
[9]  
Duan J, 2016, Chin J Front Med Sci, V8, P17, DOI [10.3969/l.issn.1674-7372.2016.07.005, DOI 10.3969/J.ISSN.1674-7372.2016.07.005]
[10]   Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J].
Ferlay, Jacques ;
Soerjomataram, Isabelle ;
Dikshit, Rajesh ;
Eser, Sultan ;
Mathers, Colin ;
Rebelo, Marise ;
Parkin, Donald Maxwell ;
Forman, David ;
Bray, Freddie .
INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) :E359-E386